<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2018-1-1-15-18</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛУЧЕВАЯ ТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RADIOTHERAPY</subject></subj-group></article-categories><title-group><article-title>Современное состояние клинической нейтрон-захватной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Current Status of Clinical Neutron Capture Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Липенгольц</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lipengolts</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">lipengolts@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Григорьева</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Grigorieva</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулаков</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulakov</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шейно</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sheino</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ;&#13;
Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России;  &#13;
Национальный исследовательский ядерный университет «МИФИ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Blokhin National Medical Research Center of Oncology; &#13;
A.I. Burnasyan Federal Medical Biophysical Center; &#13;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Blokhin National Medical Research Center of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2018</year></pub-date><volume>1</volume><issue>1</issue><fpage>15</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Липенгольц А.А., Григорьева Е.Ю., Иванов С.М., Кулаков В.Н., Шейно И.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Липенгольц А.А., Григорьева Е.Ю., Иванов С.М., Кулаков В.Н., Шейно И.Н.</copyright-holder><copyright-holder xml:lang="en">Lipengolts A.A., Grigorieva E.Y., Ivanov S.M., Kulakov V.N., Sheino I.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/34">https://www.oncoradjournal.ru/jour/article/view/34</self-uri><abstract><p>Проведен анализ современного состояния клинической нейтрон-захватной терапии (НЗТ) в мире. На примере Японии, являющейся мировым лидеров по количеству случаев применения НЗТ, показано увеличение ежегодного количества сеансов НЗТ в Японии. Помимо увеличения количества пациентов, наблюдающегося в Японии с 2003 г., увеличивается и перечень локализаций злокачественных заболеваний, к которым применяется НЗТ. За последние 20 лет количество типов злокачественных опухолей, для которых была использована НЗТ, увеличилось с 2 до 12. Это говорит о все возрастающем интересе со стороны врачей в Японии к НЗТ как методу лечения злокачественных новообразований. В обзоре приводятся статистические данные эффективности НЗТ в лечении опухолей головного мозга, опухолей головы и шеи, а также меланомы кожи. На основании статистических данных делается вывод, что лечение опухолей головы и шеи при помощи НЗТ в настоящее время является наиболее перспективным направлением, показавшим уникальную терапевтическую эффективность, не доступную другим методам лечения. С точки зрения технической реализации процедуры НЗТ наблюдается переход от использования в качестве источника нейтронов исследовательских ядерных реакторов к специализированным маломощным ядерным реакторам медицинского назначения и нейтронным генераторам на основе ускорителей. Приведены данные по существующим и создаваемым центрам НЗТ на основе нейтронных генераторов.</p></abstract><trans-abstract xml:lang="en"><p>Neutron capture therapy (NCT) is a method of beam radiotherapy like conventional radiotherapy and proton therapy. The main advantage of NCT over other methods is its high self targeting tumor selectivity based on physical phenomenon of neutron capture. NCT has been used for curing cancer in patients in nine countries. Currently four countries continue treating patients with NCT. Most of the patients treated with NCT were treated in nuclear reactors. At present new accelerator-based neutron sources for NCT are being developed. Shift from nuclear reactor based neutron source to accelerator base neutron source can be observed all around the world. First clinical trials of NCT with accelerator based neutron sources are being held in Japan. Brain tumors and head and neck cancer are the major subject for NCT by now. Clinical outcomes of NCT are reviewed. Annual number of patient as well as number of tumor types are treated with NCT are increasing in Japan. Future prospects of NCT in curing malignancies are analyzed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лучевая терапия</kwd><kwd>нейтрон-захватная терапия</kwd><kwd>опухоли мозга</kwd><kwd>опухоли головы и шеи</kwd><kwd>меланома</kwd><kwd>нейтронные генераторы</kwd><kwd>клинические испытания</kwd></kwd-group><kwd-group xml:lang="en"><kwd>radiotherapy</kwd><kwd>neutron capture therapy</kwd><kwd>brain tumors</kwd><kwd>head and neck cancer</kwd><kwd>melanoma</kwd><kwd>neutron generators</kwd><kwd>clinical trials</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Locher G.L. Biological effects and therapeutic possibilities of neutrons // Amer. J. Roentgenol. Radium Ther. 1936. Vol. 36. № 1. P. 1–13.</mixed-citation><mixed-citation xml:lang="en">Locher G.L. Biological effects and therapeutic possibilities of neutrons // Amer. J. Roentgenol. Radium Ther. 1936. Vol. 36. № 1. P. 1–13.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Farr L.E., Sweet W.H., Locksley H.B., Robertson J.S. Neutron capture therapy of gliomas using boron-10 // Trans. Amer. Neurol. Assoc. 1954. Vol. 79. P. 110–113.</mixed-citation><mixed-citation xml:lang="en">Farr L.E., Sweet W.H., Locksley H.B., Robertson J.S. Neutron capture therapy of gliomas using boron-10 // Trans. Amer. Neurol. Assoc. 1954. Vol. 79. P. 110–113.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Miyatake S.-I., Kawabata S., Hiramatsu R. et al. Boron neutron capture therapy for malignant brain tumors // Neurol. Med. Chir. (Tokyo). 2016. P. 361–371. doi:10.2176/nmc.ra.2015-0297.</mixed-citation><mixed-citation xml:lang="en">Miyatake S.-I., Kawabata S., Hiramatsu R. et al. Boron neutron capture therapy for malignant brain tumors // Neurol. Med. Chir. (Tokyo). 2016. P. 361–371. doi:10.2176/nmc.ra.2015-0297.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kumada H. Development for accelerator-based BNCT devices in University of Tsukuba // In: BNCT Workshop, 22th of May, Bialystok, Poland. – Bialystok. 2017.</mixed-citation><mixed-citation xml:lang="en">Kumada H. Development for accelerator-based BNCT devices in University of Tsukuba // In: BNCT Workshop, 22th of May, Bialystok, Poland. – Bialystok. 2017.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barth R.F., Vicente M.G.H., Harling O.K. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer // Radiat. Oncol. 2012. Vol. 7. P. 1–21.</mixed-citation><mixed-citation xml:lang="en">Barth R.F., Vicente M.G.H., Harling O.K. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer // Radiat. Oncol. 2012. Vol. 7. P. 1–21.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kankaanranta L., Seppälä T., Koivunoro H. et al. l-Boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: A phase I study // Int. J. Radiat. Oncol. 2011. Vol. 80. № 2. P. 369–376. doi:10.1016/j.ijrobp.2010.02.031.</mixed-citation><mixed-citation xml:lang="en">Kankaanranta L., Seppälä T., Koivunoro H. et al. l-Boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: A phase I study // Int. J. Radiat. Oncol. 2011. Vol. 80. № 2. P. 369–376. doi:10.1016/j.ijrobp.2010.02.031.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kato I., Fujita Y., Maruhashi A. et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies // Appl. Radiat. Isot. 2009. Vol. 67. Suppl. 7–8. doi:10.1016/j.apradiso.2009.03.103.</mixed-citation><mixed-citation xml:lang="en">Kato I., Fujita Y., Maruhashi A. et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies // Appl. Radiat. Isot. 2009. Vol. 67. Suppl. 7–8. doi:10.1016/j.apradiso.2009.03.103.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Aihara T., Morita N., Kamitani N. et al. BNCT for advanced or recurrent head and neck cancer // Appl. Radiat. Isot. 2014. Vol. 88. P. 12–15. doi:10.1016/j.apradiso.2014.04.007.</mixed-citation><mixed-citation xml:lang="en">Aihara T., Morita N., Kamitani N. et al. BNCT for advanced or recurrent head and neck cancer // Appl. Radiat. Isot. 2014. Vol. 88. P. 12–15. doi:10.1016/j.apradiso.2014.04.007.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki M., Kato I., Aihara T. et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer // J. Radiat. Res. 2014. Vol. 55. № 1. P. 146–153. doi:10.1093/jrr/rrt098.</mixed-citation><mixed-citation xml:lang="en">Suzuki M., Kato I., Aihara T. et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer // J. Radiat. Res. 2014. Vol. 55. № 1. P. 146–153. doi:10.1093/jrr/rrt098.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kankaanranta L., Seppälä T., Koivunoro H. et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial // Int. J. Radiat. Oncol. 2012. Vol. 82. № 1. P. e67–e75. doi:10.1016/j.ijrobp.2010.09.057.</mixed-citation><mixed-citation xml:lang="en">Kankaanranta L., Seppälä T., Koivunoro H. et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial // Int. J. Radiat. Oncol. 2012. Vol. 82. № 1. P. e67–e75. doi:10.1016/j.ijrobp.2010.09.057.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L.-W., Chen Y.-W., Ho C.-Y. et al. Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I/II trial // Int. J. Radiat. Oncol. 2016. Vol. 95. № 1. P. 396–403. doi:10.1016/j.ijrobp.2016.02.028.</mixed-citation><mixed-citation xml:lang="en">Wang L.-W., Chen Y.-W., Ho C.-Y. et al. Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I/II trial // Int. J. Radiat. Oncol. 2016. Vol. 95. № 1. P. 396–403. doi:10.1016/j.ijrobp.2016.02.028.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kankaanranta L., Saarilahti K., Mäkitie A. et al. Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement // Radiother. Oncol. 2011. Vol. 99. № 1. P. 98–99. doi:10.1016/j.radonc.2011.02.008.</mixed-citation><mixed-citation xml:lang="en">Kankaanranta L., Saarilahti K., Mäkitie A. et al. Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement // Radiother. Oncol. 2011. Vol. 99. № 1. P. 98–99. doi:10.1016/j.radonc.2011.02.008.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Haapaniemi A., Kankaanranta L., Saat R. et al. Boron neutron capture therapy in the treatment of recurrent laryngeal cancer // Int. J. Radiat. Oncol. 2016. Vol. 95. № 1. P. 404–410. doi:10.1016/j.ijrobp.2015.11.010.</mixed-citation><mixed-citation xml:lang="en">Haapaniemi A., Kankaanranta L., Saat R. et al. Boron neutron capture therapy in the treatment of recurrent laryngeal cancer // Int. J. Radiat. Oncol. 2016. Vol. 95. № 1. P. 404–410. doi:10.1016/j.ijrobp.2015.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Moss R.L. Critical review, with an optimistic outlook, on boron neutron capture therapy (BNCT) // Appl. Radiat. Isot. 2014. Vol. 88. P. 2–11. doi:10.1016/j.apradiso.2013.11.109.</mixed-citation><mixed-citation xml:lang="en">Moss R.L. Critical review, with an optimistic outlook, on boron neutron capture therapy (BNCT) // Appl. Radiat. Isot. 2014. Vol. 88. P. 2–11. doi:10.1016/j.apradiso.2013.11.109.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fukuda H., Hiratsuka J., Kobayashi T. et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor // Australas Phys. Eng. Sci. Med. 2003. Vol. 26. № 3. P. 97–103. doi:10.1007/BF03178777.</mixed-citation><mixed-citation xml:lang="en">Fukuda H., Hiratsuka J., Kobayashi T. et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor // Australas Phys. Eng. Sci. Med. 2003. Vol. 26. № 3. P. 97–103. doi:10.1007/BF03178777.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yong Z., Song Z,. Zhou Y. et al. Boron neutron capture therapy for malignant melanoma: first clinical case report in China // Chin. J. Cancer Res. 2016. Vol. 28. № 6. P. 634–640. doi:10.21147/j.issn.1000-9604.2016.06.10.</mixed-citation><mixed-citation xml:lang="en">Yong Z., Song Z,. Zhou Y. et al. Boron neutron capture therapy for malignant melanoma: first clinical case report in China // Chin. J. Cancer Res. 2016. Vol. 28. № 6. P. 634–640. doi:10.21147/j.issn.1000-9604.2016.06.10.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kreiner A.J., Bergueiro J., Cartelli D. et al. Present status of accelerator-based BNCT // Rep. Pract. Oncol. Radiother. 2016. Vol. 21. № 2. P. 95–101. doi:10.1016/j.rpor.2014.11.004.</mixed-citation><mixed-citation xml:lang="en">Kreiner A.J., Bergueiro J., Cartelli D. et al. Present status of accelerator-based BNCT // Rep. Pract. Oncol. Radiother. 2016. Vol. 21. № 2. P. 95–101. doi:10.1016/j.rpor.2014.11.004.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
